Stock PARNELL PHARMACEUTICALS HOLDINGS LTD
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Parnell Pharmaceuticals Holdings Ltd OTC Bulletin Board

Equities

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for Parnell Pharmaceuticals Holdings Ltd
2022 Parnell Pharmaceuticals Holdings Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
2021 DW Healthcare Partners V, L.P. managed by DW Healthcare Partners completed the acquisition of a 29% stake in Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARN.F) for $2.5 million CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Parnell Pharmaceuticals : Welcomes Dr. Chelsie Estey as Vice President of U.S. Pet Care
PU
Parnell Pharmaceuticals : Adds Three Experts to Leadership Team
PU
Parnell Pharmaceuticals : Two New Territory Business Managers Help Parnell Better Serve Producers and Veterinarians
PU
Parnell Pharmaceuticals Holdings Ltd Announces Extension of Rights Offering
PR
Parnell Pharmaceuticals Holdings Ltd Announces Commencement of Rights Offering
PR
Parnell Pharmaceuticals Gives Notice of Annual General Meeting and Explanatory Memorandum
AQ
Parnell Pharmaceuticals Holdings Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
CI
DW Healthcare Partners V, L.P. managed by DW Healthcare Partners completed the acquisition of a 29% stake in Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARN.F) for $2.5 million
CI
DW Healthcare Partners V, L.P. managed by DW Healthcare Partners made an offer to acquire Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARN.F) for $7.2 million.
CI
Parnell Pharmaceuticals Announces Nomovid Antiviral Nasal Spray
CI
Parnell Pharmaceuticals Holdings Ltd Reports Earnings Results for the Half Year Ended June 30, 2019
CI
Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Full Year Ended 31 December 2018; Provides Earnings Guidance for the Year 2019
CI
Parnell Pharmaceuticals Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the Nine Months Ended September 30, 2018; Revises Revenue Guidance for the Year 2018
CI
Parnell Pharmaceuticals Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018; Revised Earnings Guidance for the Full Year 2018
CI
Parnell Pharmaceuticals Holdings Ltd Reports Audited Earnings Results for the First Quarter Ended March 31, 2018; Revises Earnings Guidance for the Year 2018
CI
Parnell Pharmaceuticals Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2017; Provides Earnings Guidance for the Year 2017
CI
Certain Ordinary Shares of Parnell Pharmaceuticals Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-MAR-2017.
CI
Certain Options of Parnell Pharmaceuticals Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-MAR-2017.
CI
Certain Warrants of Parnell Pharmaceuticals Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-MAR-2017.
CI
Parnell Pharmaceuticals Holdings Ltd. Announces Consolidated Earnings Results for the Year Ended December 31, 2016; Provides Earnings Guidance for the Year 2017
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PARNF Stock
  4. Stock
  5. News Parnell Pharmaceuticals Holdings Ltd